|
|
Clinical effect of bone marrow combined w ith peripheral blood haploidentical hematopoietic stem cell transp lantation in the treatment of acute leukem ia |
XU Xiao-li |
Department of Hematology,the First People′s Hospital of Foshan City in Guangdong Province,Foshan 528000,China |
|
|
Abstract ObjectiveTo explore the clinical effect of bone marrow combined with peripheral blood haploid-matched hematopoietic stem cell transplantation in the treatment of acute leukemia.MethodsFifty-three patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation in our hospital from January 2007 to January 2016 were retrospectively analyzed.According to different transplantation methods,they were divided into experimental group(22 cases)and control group(31cases).Patients in experimental group were treated with bonemarrow combined with peripheral blood haploid hematopoietic stem cell transplantation,patients in control group were treated with bonemarrow stem cell transplantation,and peripheral blood stem cells in the experimentweremobilized by G-CSF.The recovery of blood cells,incidence of acute graft-versus-host disease(aGVHD),transplantation-related mortality,2 years recurrence rate and survival rate and adverse reaction rate were compared between the two groups.ResultsThe survival rate of patients in the experimental group was higher than that in the control group,while the recurrence rate and incidence rate of aGVHD were lower than that in the control group,the difference was statistically significant(P<0.05).The blood routine indexes of patients in the experimental group after transplantation and follow-up were higher than those in the control group,and the differencewas statistically significant(P<0.05).The incidence of adverse events in the experimental group was lower than that in the control group,and the difference was statistically significant(P<0.05).ConclusionBonemarrow combined with peripheral blood haploidentical hematopoietic stem cell transplantation is of great significance in the treatment of acute leukemia,and can reduce the recurrence rate and incidence of aGVHD on the basis of improving the quality of life.It isworth applying and popularizing.
|
|
|
|
|
[1] |
赵潇溟,胡晓霞,王健民.异基因造血干细胞移植后骨髓免疫微环境重建研究[J].中国免疫学杂志,2016,32(9):1249-1252.
|
[2] |
王昱.单倍型造血干细胞移植治疗骨髓增生异常综合征的进展[J].中华血液学杂志,2017,38(4):348-351.
|
[3] |
张苏东.异基因造血干细胞移植治疗骨髓增生异常综合征研究进展[J].中华血液学杂志,2016,37(5):432-436.
|
[4] |
陈育红.“去甲基化”时代论异基因造血干细胞移植治疗骨髓增生异常综合征的进展[J].国际输血及血液学杂志,2013,36(4):388-391.
|
[8] |
孙于谦.复发白血病异基因造血干细胞移植后疗效的改进策略[J].中华血液学杂志,2017,38(8):732-736.
|
[6] |
李珍,张龚莉,周健.骨髓增生异常综合征异基因造血干细胞移植后12年出现急性髓系白血病一例报告并文献复习[J].中华血液学杂志,2014,35(1):63-65.
|
[7] |
汪剑丽.骨髓基质细胞在白血病造血微环境中的作用及其研究进展[J].实用医学杂志,2016,32(7):1182-1184.
|
[8] |
李云双,陈永升,聂伟业.小剂量地西他滨联合异基因造血干细胞分次输注治疗老年骨髓增生异常综合征转急性髓性白血病 2 例报告[J].广西医学,2015,37(10):1393-1396.
|
[9] |
吴沙,张诚,张曦.减低强度预处理药物在急性髓系白血病/骨髓增生异常综合征患者造血干细胞移植中的应用[J].中国药房,2015,26(14):1877-1880.
|
[10] |
蔡大利,高峰,高然,等.异基因造血干细胞移植治疗急性髓系白血病以及骨髓增生异常综合征[J].中国医科大学学报,2017,46(1):45-49.
|
[12] |
吴倩,何广胜,吴德沛,等.地西他滨桥接异基因造血干细胞移植治疗骨髓增生异常综合征和急性髓样白血病的临床可行性和疗效研究[J].肿瘤,2013,33(3):264-270.
|
[13] |
曾钊宇,张宇,杨洁飞,等.白血病化疗患者骨髓造血功能恢复的评估意义[J].现代检验医学杂志,2013,45(4):148-150.
|
[14] |
颜平康,张前杏,蔡文亮,等.从骨髓造血功能亢奋探讨急性白血病的治疗[J].江西中医药大学学报,2016,28(2):122-124.
|
[11] |
Peccatori J,Forcina A,Clerici D,et al.Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cellsand permits peripheralblood stem cell transplantation from haploidentical donors[J].Leukemia,2015,29(2):396.
|
[15] |
刘灿.白血病异基因造血干细胞移植后复发的预防[J].中华血液学杂志,2013,34(8):729-732.
|
|
|
|